NLRP3 and obesity due to melanocortin 4 receptor deficiency: Our findings suggest that the serum lipid-lowering treatments may alleviate obesity-induced AHR and lung fibrosis through anti-inflammatory responses by inhibition of RAS and NLRP3 inflammasome, and CCK activity.